Premium
Reappraisal of Contemporary Pharmacokinetic and Pharmacodynamic Principles for Informing Aminoglycoside Dosing
Author(s) -
Bland Christopher M.,
Pai Manjunath P.,
Lodise Thomas P.
Publication year - 2018
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/phar.2193
Subject(s) - dosing , medicine , aminoglycoside , pharmacokinetics , pharmacodynamics , therapeutic drug monitoring , intensive care medicine , minimum inhibitory concentration , antibiotics , pharmacology , cmax , area under the curve , therapeutic index , antimicrobial , drug , biology , microbiology and biotechnology
Therapeutic drug management is regularly performed for aminoglycosides in an effort to maximize their effectiveness and safety. The ratio of maximum plasma drug concentration to minimum inhibitory concentration (Cmax/ MIC ) has long been regarded as the primary pharmacokinetic/pharmacodynamic ( PK / PD ) index of clinical efficacy for aminoglycosides due to their concentration‐dependent killing. In this review, however, we discuss why the area under the plasma concentration–time curve ( AUC )/ MIC ratio may be a more reliable indicator of bacterial killing and clinical efficacy for these agents. The definitive AUC / MIC efficacy targets for aminoglycosides are less clear, unlike those that exist for fluoroquinolones. Evaluation of available literature suggests that an AUC / MIC ratio of 30–50 for aminoglycoside therapy may provide optimal outcomes when targeting non–critically ill immunocompetent patients with low–bacterial burden gram‐negative infections such as urinary tract infections or in patients receiving additional gram‐negative therapy with good source control. However, an AUC / MIC target of 80–100 may be more prudent when treating patients with aminoglycoside monotherapy or in critically ill patients with high–bacterial burden infections, such as nosocomial pneumonia. Reappraisal of current antimicrobial susceptibility breakpoints for aminoglycosides against gram‐negative bacteria may also be necessary to achieve these AUC / MIC targets and ensure that current empiric doses are not grossly suboptimal in critically ill patients. Although it has been historically difficult to calculate AUC s in clinical practice, equation‐based and Bayesian approaches now can be used to estimate the AUC in clinical practice, with limited PK sampling. Additional research is needed to better define optimal AUC / MIC targets for efficacy, especially when drugs are used in combination, as well as PK / PD targets associated with suppression of resistance. It is also important to determine if AUC can predict nephrotoxicity of these agents or whether trough concentrations should be used instead.